Fintel on MSN1 天
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) with Overweight Recommendation
Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...
Cantor Fitzgerald sets GH Research stock Overweight, $14 target
GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...
Cantor Fitzgerald给予GH Research"增持"评级，目标价14美元
周四 - Cantor Fitzgerald对GH Research PLC (NASDAQ: GHRS )给予"增持"评级，目标价设定为14.00美元。这一新的评级基于GHRS的GH001（一种吸入式5-MeO-DMT疗法）有望成为难治性抑郁症（TRD）标准疗法的潜力。Cantor ...
GH Research initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of GH Research (GHRS) with an Overweight rating and $14 price target Maximize Your Portfolio with Data ...
Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback
FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.
GH Research PLC's (NASDAQ:GHRS) Top Key Executive Florian Schonharting is the most upbeat ...
Key Insights GH Research's significant insider ownership suggests inherent interests in company's expansion A total ...